Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
277 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05336279 | Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition | completed | Phase 1 | 28 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT05607693 | A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects | unknown | Phase 1 | 52 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT04335006 | A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. | terminated | Phase 3 | 80 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT05661591 | Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects | completed | Phase 1 | 18 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05792410 | A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer. | unknown | Phase 1 / Phase 2 | 300 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Mar 31, 2023 | clinicaltrials |
| NCT05515289 | Study of SHR6390 in Renal Insufficiency and Healthy Subjects | unknown | Phase 1 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 10, 2023 | clinicaltrials |
| NCT01192971 | A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma(HCC) | completed | Phase 2 | 121 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT02721589 | A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects | completed | Phase 1 | 126 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02738489 | A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma | completed | Phase 1 | 36 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02742935 | A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects | completed | Phase 1 | 99 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT03085069 | A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC | unknown | Phase 2 | 146 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04676035 | The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole | completed | Phase 1 | 18 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05560360 | A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05147727 | Drug-drug Interaction Study Between Fluconazole and Famitinib in Healthy Subjects | completed | Phase 1 | 22 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05252546 | Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects | completed | Phase 1 | 36 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05214976 | A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients | unknown | Phase 2 | 64 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05592262 | Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 19, 2022 | clinicaltrials |
| NCT03691090 | Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer | completed | Phase 3 | 596 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03863223 | A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer | unknown | Phase 3 | 590 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 23, 2022 | clinicaltrials |
| NCT05042375 | A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 450 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT03664297 | Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor | unknown | Phase 1 | 86 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT03774979 | SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors | unknown | Phase 1 | 193 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04322552 | A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects | completed | Phase 1 | 18 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT03491631 | Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors | unknown | Phase 1 | 23 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 4, 2022 | clinicaltrials |
| NCT03856541 | A Study of SHR-A1403 in Patients With Advanced Solid Tumor | completed | Phase 1 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04414150 | A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours | completed | Phase 1 | 28 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 26, 2022 | clinicaltrials |
| NCT04457180 | A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects | completed | Phase 1 | 18 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 26, 2022 | clinicaltrials |
| NCT02973737 | A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer | unknown | Phase 3 | 279 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 25, 2022 | clinicaltrials |
| NCT05440006 | A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05425472 | A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer | unknown | Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT03182673 | The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 31 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT03596658 | SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer | terminated | Phase 1 | 4 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT04985136 | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 3 | 1 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT03945604 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC | completed | Phase 1 | 32 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 12, 2022 | clinicaltrials |
| NCT04108676 | Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects | completed | Phase 1 | 16 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04428086 | A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects. | completed | Phase 1 | 19 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 26, 2022 | clinicaltrials |
| NCT03121716 | A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects | completed | Phase 1 | 23 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT02684266 | A Study of SHR6390 in Advanced Solid Tumor Patients | completed | Phase 1 | 40 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03904823 | A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC | unknown | Phase 2 | 58 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 7, 2022 | clinicaltrials |
| NCT04108247 | A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC | unknown | Phase 1 | 39 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 7, 2022 | clinicaltrials |
| NCT02426034 | A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer | completed | Phase 4 | 2,004 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03075462 | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | completed | Phase 1 | 98 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03509636 | A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer | completed | Phase 1 | 113 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03707509 | Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 3 | 263 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT04041011 | A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients | completed | Phase 1 | 23 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04229615 | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | unknown | Phase 3 | 690 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03711305 | Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | unknown | Phase 3 | 462 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2022 | clinicaltrials |
| NCT02764268 | Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer | completed | N/A | 60 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04862091 | Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer | completed | Phase 2 | 69 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 4, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials